Introduction
Macrophages can form a significant proportion of the solid tumour mass and consequently play an important role in tumour progression. 1 The role of macrophages in tumorigenesis remains controversial as they can display both a growth promoting as well as a tumoricidal phenotype. 2, 3 The tumoricidal properties of macrophages have been exploited in human cancer therapy. Clinical protocols involve the transfer of patient-derived macrophages that have been matured and activated with IFN␥ ex vivo before administration. To date these studies have reported only a few side-effects, such as low grade fevers and chills. 3 However despite localisation, minimal efficacy was observed implying that activated macrophages per se are not potent enough to mediate significant therapeutic activity. The strategy we describe here aims to remedy this by 'arming' macrophages with a therapeutic gene to effect gene dependent enzyme prodrug therapy (GDEPT). 4 In this way a non-toxic enzyme can be delivered to the tumour and subsequent application of a prodrug provides therapeutic activity at the site of gene expression. The particular enzyme/prodrug combination that we have used, human cytochrome P450/ cyclophosphamide, permits significant bystander activity through local diffusion of the activated metabolite. 4 Macrophages have been associated with poor prognosis 5 and predominate in regions of tissue necrosis, 6 where oxygen tension is low (hypoxia). This tumour Infiltration of transduced macrophages into a tumour spheroid results in induction of gene expression. We demonstrate significant tumour cell killing only in the presence of cyclophosphamide via activation by P4502B6 and show that this can be further targeted to tumours through hypoxia regulated gene expression. Gene Therapy (2000) 7, 255-262.
hypoxia is thought to be primarily caused by deficiencies in the tumour blood supply and solid tumours often have large areas of both chronic and acute hypoxia. It is cells in these areas that are thought to be responsible for the repopulation of tumours after treatment as they are often radiation-and chemotherapy-resistant. 7 The mammalian cellular response to hypoxia is, in part, mediated through the stabilisation of members of certain of the basic helixloop-helix-PAS (bHLH-PAS) transcription factor family, typified by hypoxia inducible factors 1 and 2 (HIF-1, HIF-2/EPAS), and subsequent binding to DNA enhancer sequences known as hypoxia response elements (HREs). 8 HREs are found in either the 5Ј or 3Ј regions of a number of genes including those encoding phosphoglycerate kinase, erythropoietin and vascular endothelial growth factor (VEGF). 8 Solid tumour hypoxia has been previously identified as a potent trigger for transcriptionally targeted gene therapy via HRE sequences and this approach has been modelled using stably transfected tumour cells. 9 Macrophages have been reported to respond to anoxia and hypoxia by a number of changes including adoption of an angiogenic phenotype 10 as well as increases in TNF␣ (tumour necrosis factor ␣) and IL-6 production. 11, 12 Hypoxia has also been implicated in the down-regulation of TNF-␣ induced MCP-1 (monocyte chemoattractant protein-1) expression in ovarian tumours and this may affect macrophage distribution patterns. 6 Mouse macrophages are able to respond to a combination of IFN␥ (interferon gamma) and hypoxia via both an interferon response element and an HRE in the promoter region of the iNOS (inducible nitric oxide synthase) gene to cause up-regulation of iNOS protein production. 13 Human macrophages do not have an analogous response in the iNOS gene due to species differences in the promoter, although they have been shown to up-regulate VEGF in response to combinations of hypoxia and LPS (lipopolysaccharide) and IFN␥.
14 There are no published data on the role of the HIF-1/HRE pathway in the response of primary human macrophages to hypoxia.
We wished to demonstrate the application of macrophage-mediated GDEPT and furthermore increase the specificity of the approach. To this end we first determined that there is a transcriptional response to hypoxia in primary human macrophages. We then configured the CYP2B6 gene into a hypoxia-regulated adenoviral vector (AdOBHRE 15 ) and demonstrated a significant induction of gene expression via the HIF/HRE pathway in primary human macrophages.
We have demonstrated the infiltration of macrophages into a tumour model, their constitutive expression of a therapeutic gene and the attendant cytotoxic effects on tumour cells when prodrug is added. Additionally we have shown that primary human macrophages can induce gene expression in response to hypoxia via HRE sequences, and used this to constrain the GDEPT approach preferentially to the tumour target site. This strategy would avoid activation in the systemic circulation or non-pathological sites.
Results
Macrophage-mediated gene delivery into tumour spheroids Isolated monocytes were differentiated in Teflon culture systems. Morphology and antibody staining analysis of CD68, CD16 and Cd11c markers confirmed the differentiated phenotype. Differentiated macrophages were transduced with adenoviral vectors incorporating the lacZ reporter gene under control of the constitutive CMV promoter (Ad-CMV-lacZ). Gene transfer efficiencies were routinely greater than 80% (Figure 1a) .
We sought to determine whether primary human macrophages that had been transduced with adenoviral vectors could infiltrate solid tissues. To test this we used the spheroid model system. Spheroids are threedimensional multicellular aggregates that can be used to model the avascular tumour microenvironment. 16 We established spheroids from the breast cancer cell line T47D. Primary human macrophages and macrophages engineered with Ad-CMV lacZ or Ad-CMV GFP were added to T47D spheroids and after 2 days the spheroids were washed thoroughly, fixed and either X-gal stained (Figure 1b and c) or sectioned and stained for ␤-galactosidase (Figure 1d ) and the presence of CD68, a macrophage marker (Figure 1e ). No differences in macrophage distribution were observed between naive and Ad-CMV lacZ transduced macrophages (not shown), and no blue staining was observed with the Ad-CMV-GFP macrophages (Figure 1c ). Macrophages were found to have entered the spheroid mass indicating that they had infiltrated into the tissue.
Macrophage-mediated GDEPT Cyclophosphamide, a prodrug with the ability to effect bystander killing, is widely used in cancer chemotherapy. It is converted to its active metabolite 4-hydroxycyclophosphamide by the cytochrome P450 enzymes and this conversion normally takes place in the liver where these enzymes are abundant. Delivery of this enzyme to the locality of tumour cells can sensitise them to the cytotoxic effects of cyclophosphamide as the active metabolite can diffuse through cell membranes and is intracellularly converted to phosphoramide mustard thereby causing damage to DNA. 4 Diffusion of the active metabolite means that there is a significant bystander effect with this particular GDEPT approach. The numbers of macrophages that would infiltrate tumours in a therapeutic scenario is likely to be less than the number of tumour target cells making this strategy particularly appropriate for macrophage-mediated cell killing.
We wished to examine whether macrophages expressing cytochrome P450 were capable of enhancing the cytotoxic effect of cyclophosphamide on tumour cells. We engineered macrophages using adenoviral vectors to express cytochrome P450 (along with a GFP marker) under CMV control. These constructs had similar expression characteristics in primary human macrophages to the former lacZ constructs and the cytochrome P450 was found to retain enzymatic activity (data not shown). Macrophages themselves were largely unaffected by cyclophosphamide, even when expressing cytochrome P450 (Figure 2a ). This is particularly useful as macrophages will be able to produce therapeutically active metabolite over a long term without rendering themselves susceptible. Expression of reporter gene by transduced macrophages has been assayed after 3 weeks and was still detectable (data not shown).
Spheroid and macrophage co-culture was performed for 2 days after which the spheroids were washed to remove excess surface macrophages and leave only infiltrated macrophages. Treatment of the Ad-CMV CYP2B6 infiltrated spheroids with cyclophosphamide showed both a significant reduction in volume (indicating growth delay) and gross morphological damage, but little effect was noted with Ad-CMV GFP controls ( Figure 2b ). Clonogenic assay on disaggregated spheroids indicated significantly reduced numbers of cells from the cyclophosphamide-treated spheroids infiltrated with macrophages engineered with Ad-CMV-CYP2B6 ( Figure 2c ).
Application of hypoxia targeted gene therapy to macrophage mediated gene delivery
The potency of the approach demonstrated above indicates a requirement for targeting of therapeutic gene expression. We have developed a range of optimised hypoxia responsive promoters that target gene expression to ischemic sites. We wished to apply this technology to macrophage delivery, however there are no data on the ability of primary human macrophages to respond to hypoxia via the HRE-mediated pathway.
To assess the potential for HRE-mediated gene expression, total RNA was prepared from primary human macrophages and analysed by RPA (ribonuclease protection assay) using probes specific for HIF-1␣ and HIF 2␣. Significant levels of RNA were detected with each probe (Figure 3a) , however HIF-2␣ levels were approximately seven-fold higher than HIF-1␣ as measured by densitometry. Protein extracts were prepared from primary human macrophages after exposure to normoxic and hypoxic conditions and analysed by Western blotting using antibodies specific for HIF-1␣ and HIF 2␣ 
Figure 1 Infiltration of Ad-CMV lacZ transduced macrophages into T47D spheroids (a) inset of X-gal stained Ad-CMV lacZ transduced macrophages. These macrophages, along with Ad-CMV GFP controls were infiltrated into spheroids and X-gal stained; (b) Ad-CMV-lacZ, (c) Ad-CMV-GFP. Histological sections of spheroids infiltrated with Ad-CMV lacZ transduced macrophages showing gene expression within the spheroid, (d) ␤-galactosidase and (e) CD68 by peroxidase-based immunodetection.
under either condition. These data demonstrate that primary human macrophages express HIF family ␣-subunits. Failure to detect HIF-1␣ protein by Western blotting is in contrast to results in other cell lines studied 17 and may relate to particular difficulties in extracting this labile protein from macrophages.
Macrophage-mediated delivery of hypoxia regulated genes into tumour spheroids We have generated a novel adenoviral vector system (Ad-OBHRE) that utilises an optimised hypoxia responsive promoter to target transcription to tissues under low oxygen tensions. We transduced primary human macrophages with Ad-OBHRE reporter vectors and exposed these transduced cells to hypoxic conditions. Gene expression under normoxia was barely detectable but was highly induced under hypoxia to levels comparable with CMV 15 (data not shown). This further demonstrates that macrophages can sustain HRE-regulated gene expression (Figure 4a and b) .
Our next step was to demonstrate that natural hypoxia would be sufficient to induce expression in these transduced macrophages. The avascular spheroid model has been shown to mimic low oxygen conditions that exist in solid tumours. 16 We therefore treated breast tumour spheroids maintained under normoxia with macrophages transduced with Ad-OBHRE lacZ. Before infiltration into the spheroid, as reported above, there was no lacZ gene expression detectable in the macrophages under normoxia. However after infiltration ␤-galactosidase expression was clearly detected in macrophages within Gene Therapy the spheroid as revealed by whole mount staining with X-gal (Figure 4c ). The numbers of macrophages expressing ␤-galactosidase appeared visibly less than when Ad-CMV lacZ engineered macrophages were used. We reasoned that this might reflect the fact that significant areas of sufficiently low levels of hypoxia were not present throughout the spheroid to activate expression in all the infiltrated macrophages. We therefore incubated spheroids post-infiltration under hypoxia ( Figure 4d ) and under these conditions an increase in the number of macrophages expressing lacZ was detected. In normoxic spheroids ␤-galactosidase expression was confirmed by staining with antibodies against ␤-galactosidase and CD68 (Figure 4e and f) . These data confirm that therapeutic gene expression can be specifically activated by the natural hypoxia that exists in an avascular tissue mass. The data also demonstrate the selectivity of expression in that significant hypoxia is required to achieve full expression.
To confirm that the HRE driven expression of CYP2B6 could mediate GDEPT, macrophages were transduced with Ad-OBHRE CYP2B6. CYP2B6 expression was significantly induced by hypoxia ( Figure 5 ) and activity was confirmed by a P4502B6 biological activity assay (data not shown). Macrophages transduced with Ad-OBHRE CYP2B6 were used to infiltrate spheroids. Subsequent exposure to cyclophosphamide caused a reduction in volume of the spheroids, again indicating that cell proliferation had been inhibited. In addition there had been significant cell death within the spheroid as morphological and histological analysis revealed a decrease in the size of the viable outer rim and an increase in the proportion of necrotic cells (Figure 6a ). Disaggregation and plating of cells derived from treated spheroids further demonstrates a marked decrease in clonogenic survival ( Figure  6b ). These data demonstrate that HRE-regulated GDEPT shows significant efficacy in the spheroid tumour model and adds an improved safety profile to a potent and novel gene therapy approach.
Discussion
In this study we demonstrate the potential of using macrophages as a cell-based delivery system for GDEPT. Macrophage-mediated delivery of the CYP2B6 gene under the constitutive CMV promoter resulted in extensive tumour cell killing in the presence of the prodrug, cyclophosphamide. Given the high potency of this
Figure 3 (a) Detection of HIF-1␣ and HIF-2␣ by ribonuclease protection in HeLa cells and macrophages under normoxia (21% O 2 ). (b) Changes in HIF-1␣ and HIF-2␣ detection by Western blot of T47D cells and macrophages exposed to normoxia (21% O 2 ) and hypoxia (0.1% O 2 ). T47D cells are included as an internal control of hypoxic upregulation of HIF-1 and HIF-2␣.
approach it was desirable to impart additional tumour selectivity beyond the inherent tumour targeting of macrophages.
We considered that the natural accumulation of macrophages at sites within a hypoxic microenvironment 6 could be exploited to regulate therapeutic gene expression in response to hypoxia-mediated transcription signals. Although Maxwell et al 17 reported that a transiently transfected HRE could operate in a wide variety of cell types, primary cultures were not studied. Furthermore although a response was obtained in the human pro-monocytic cell line U937, this required more severe hypoxia and high cell density. Thus an important question was whether primary cell cultures in general, and primary human macrophages in particular, could mediate a hypoxic response via an HRE. Our data show that primary macrophages express mRNA for both regulatory HIF alpha subunits, and we found HIF-2␣ protein in hypoxic (but not normoxic) primary macrophages. Although one initial report suggested that HIF-2␣ was expressed specifically in endothelium, 18 it is now clear that it is more widely expressed, and that it can activate 
Figure 4 Hypoxic induction of Ad-OBHRE lacZ in macrophages (a) 21% O 2 ; (b) 0.1% O 2 and after infiltration into spheroids; (c) 21% O 2 ; (d) 0.1% O 2 lacZ expression determined by X-gal staining. Arrows (→) indicate uninfiltrated clusters of macrophages. Note that in (c) macrophages on the spheroid surface do not appear to express detectable lacZ unless the whole spheroid culture is placed under hypoxic conditions (d). Histological sections of normoxic spheroids infiltrated with Ad-OBHRE lacZ transduced macrophages, (e) ␤-galactosidase and (f) CD68 by peroxidasebased immunodetection.

Figure 5 Production of CYP2B6 protein in macrophages transduced with Ad-CMV/OBHRE CYP2B6 as determined by Western blotting. Lane A, CYP2B6 microsome control; B and F, untransduced macrophages; C and G, macrophages transduced with Ad-CMV GFP; D and H, macrophages transduced with Ad-CMV CYP 2B6; E and I, macrophages transduced with Ad-OBHRE CYP 2B6. Lanes B-E macrophages incubated at normal oxygen tensions (21%); F-I hypoxic oxygen tension (0.1%).
an HRE. 19 Our failure to detect HIF-1␣ protein in hypoxic macrophages should be interpreted with caution, but it is possible that they are functionally dependent on HIF-2␣.
By using an adenoviral vector that carried a minimal hypoxia responsive promoter we were able to confirm that gene expression in primary human macrophages was activated by hypoxia. As no other cellular enhancer sequences are present these data further indicate that the hypoxia signalling must be mediated through the HRE enhancer and most probably involves a HIF transcription factor. We cannot however exclude the possibility that other hypoxia responsive transcription factors are involved.
The use of adenoviral vectors to mediate gene transfer into macrophages could be readily exploited in a clinical setting. It is likely that gene transfer can be improved further by using adenoviral vectors that target macrophages 20 and by using 'gutless' vectors to minimise any adverse immunological responses against adenoviral proteins expressed in engineered macrophages. It may also be possible to use other less immunogenic vectors such as lentiviral vectors to engineer macrophages although efficiencies currently lag behind those achievable with adenoviral vectors. 21 We have shown that engineered primary human macrophages can infiltrate into tumour spheroids. Furthermore, even when the spheroids are cultured in normoxia the macrophages containing a minimal hypoxia responsive enhancer display significant gene activation. The absence of other enhancers, the absence of exogenous stimuli and the demonstration of hypoxia in spheroids 16 lead us to conclude that when macrophages infiltrate the spheroid they encounter an hypoxic environment that activates the endogenous HIF pathway to activate the HRE. The hypoxia that exists in tumours can therefore be exploited specifically to activate a therapeutic gene delivered in a macrophage.
The therapeutic application of this concept was confirmed using macrophages expressing CYP2B6 under constitutive and hypoxia-regulated control. In both cases the macrophages themselves and the target tumour cells were unaffected by treatment with cyclophosphamide. However, when the macrophage-infiltrated spheroids were treated with the prodrug, tumour cell proliferation was inhibited and there was extensive tumour cell death. There may be circumstances that warrant the use of a more aggressive macrophage-mediated therapy involving constitutive gene expression however the use of a regulated system provides an additional level of safety by imparting selectivity to the therapy.
Previous studies have demonstrated that it is possible to infuse large numbers of macrophages safely into patients and studies of macrophage trafficking have shown that monocytes and macrophages can associate with tumours with high efficiency after local administration, although significant therapeutic effects could not be demonstrated. 22 These studies and our data therefore allow us to envisage an improved therapeutic strategy for the treatment of cancer whereby the patient's macrophages are engineered ex vivo with a hypoxia-regulated gene for the expression of a prodrug activating enzyme and then returned to the tumour compartment. Following treatment of the patient with the prodrug, tumours would be selectively damaged by the macrophagemediated metabolism of the prodrug. This will only occur within the solid tumour mass and the macrophages would survive the treatment to continue acting as a metabolic centre for prodrug activation. The treatment is readily terminated by withdrawal of the prodrug and the gene therapy naturally terminates with the death of the macrophage (90 days is the approximate lifespan of this terminally differentiated cell). Inadvertent tissue damage is minimised by the natural targeting of the macrophage and the restriction of expression to sites of significant hypoxia. Other potent therapeutic genes for example cytokines, therapeutic antibodies or anti-inflammatory agents in addition to other prodrug activating enzymes could be used. Furthermore other conditions that are characterised by severe hypoxia such as arthritis and ischaemic disease could also be treated by this approach. Initially we envisage the infusion of macrophages to local sites of disease, for example an arthritic joint, an ischaemic limb or anatomically constrained malignancies such as ovarian, prostate, bladder, liver or pleural tumours. Hypoxia correlates with poor prognosis and resistance to radiation therapy in many tumour types, notably head and neck cancer, 23 thus macrophages could be used in prodrug activation systems for bioreductive drugs. It may also be possible to use systemic delivery to target distant sites of disease. In cancer, for example, even small micrometastases can be hypoxic and contain macrophages. 24 Further studies on macrophage trafficking would be needed to assess the feasibility of this approach as it is known that significant numbers of macrophages will become trapped in the liver and lung when administered systemically. 21 It may also be possible to use macrophages as a short-lived factory for the delivery of therapeutic proteins or for the in vivo delivery of viral vectors. It is possible for example to produce retroviral vectors using adenoviral vectors 25 in cultured cells and the macrophage could now be used for the selective delivery of retroviral vectors or indeed lentiviral vectors to hypoxic tissue.
In summary, we have presented data to indicate that macrophages can be used as silent carriers of a gene therapy until they infiltrate diseased tissue at which point they can respond to the hypoxic microenvironment and activate the expression of a therapeutic gene. In this way a gene therapy can be delivered specifically to large areas of diseased tissue with the potential to treat a range of diseases including disseminated cancers, inflammatory and cardiovascular disease.
Materials and methods
Isolation and culture of monocytes and macrophages Primary human monocytes were isolated from leukocyte enriched blood (National Blood Service, Bristol, UK). Blood was diluted 1:1 with RPMI 1640, layered on FicollPaque gradient (Pharmacia, Little Chalfont, UK) and centrifuged for 20 min at 400 g. The lymphocyte rich band was removed and the cells magnetically separated on the basis of CD14 expression (Miltenyi Biotech, Bisley, UK). Isolated CD14 + cells were checked for adherence (routinely above 85%). Cells were cultured in AIM-V medium (Gibco, Paisley, UK), 2% human male AB serum (Sigma, Poole, UK) for 7-10 days in teflon bags (SudLaboredarf, Gauting, Germany). Other cells lines used included T47D and HeLa (ECACC, UK).
Phenotypic markers
Cytospin preparations of 7-day-old macrophages were fixed and antibody stained using mouse monoclonal antibodies to CD16 (Serotec, Oxford, UK) and CD68 and CD11c (Dako, Cambridge, UK) and Vector ABC kit (Dako).
Construction of adenoviral vectors
The Ad-OBHRE lacZ and Ad-CMV lacZ adenoviral vectors have been described previously. 15 Ad-OBHRE CYP2B6 and Ad-CMV CYP2B6 were generated using the Microbix Biosystems (Ontario, Canada) adenoviral plasmids as follows: CYP2B6 cDNA was generated as a PCR fragment from human liver mRNA and cloned into the NheI-XbaI sites of the Promega pCI-neo mammalian expression vector to generate pCMV CYP2B6. The BglIINaeI CMV CYP2B6 fragment was then cloned into the BamHI-EcoRI of the p⌬E1sp1B Microbix transfer vector where the emcv IRES GFP cassette from pIRES2-EGFP (Clonetics, Wokingham, UK) was cloned into the XbaI site downstream of CYP2B6 to generate the pE1CMV CYP2B6 transfer vector. The oligonucleotide below (based on the 18 nucleotide hypoxia responsive element from murine phosphoglycerate kinase-1 5Ј flanking sequence 26 ) was constructed with 5Ј NheI and 3Ј XbaI compatible ends: 5Ј-CTAGAGTCGTGCAGGACGTGA CATC/TAGTGTCGTGCAGGCATC/TAGTGTCGTGCA GGACGTGACATC; TCAGCACGTCCTGCACTGTAG/ ATCACAGCACGTCCGTAG/ATCACAGCACGTCCTG Gene Therapy CACTGTAGGATC-5Ј. This was cloned into the NheI site of the PGL3 promoter vector (Promega, Southampton, UK). Replacing the luciferase reporter gene in this vector with a HindIII-XbaI CYP2B6 fragment from pCMV CYP2B6 generated the pE1 OBHRE CYP2B6 transfer vector. The EcoRI-HpaI EMCV IRES GFP fragment from pIRES2-EGFP was cloned downstream of 2B6 and the entire bicistronic expression cassette was then removed as a MluI-PshAI fragment and cloned into the p⌬E1sp1B Microbix transfer vector to generate pE1HRE CYP2B6. The recombinant Ad-OBHRE CYP2B6 and Ad-CMV CYP2B6 adenoviral vectors were generated by co-transfection of the transfer vectors with pJM17 (Microbix) in 293A cells (Quantum Biotechnologies, supplied by Kramel, Cramlington, UK). Ad-CMV GFP was obtained from Kramel. Plaques were screened for GFP expression and purified by three subsequent rounds of plaque purification. Adenoviral stocks were purified using the Arklone P fluorocarbon compound and standard CsCl gradients as previously described. 27 Adenoviral transduction of primary human macrophages Optimal transduction of macrophages was achieved with cells which had been cultured in vitro for 7-10 days in AIM-V, 2% AB serum. 3 × 10 5 cells were transduced with between 66 (Ad-CMV lacZ) and 333 (Ad-OBHRE lacZ) plaque forming units per cell (MOI), or as stated for other viruses, in a total volume of 150 l on Biofolie 25 teflon using flexiperm inserts (Hereaus, Hanau, Germany). Volume was made up with DMEM medium containing 5% fetal calf serum. After 2 h the volume was made up to 300 l and cells were incubated for a further 16 h.
Hypoxic exposure of adenovirally transduced macrophages Cells were exposed to either 0.1% or 21% O 2 in a 5% CO 2 humidified incubator (Heto, Camberley, UK) for 16 h at 37°C. Ad-CMV/OBHRE lacZ transduced cells were fixed in histological formalin and stained with X-gal substrate (Sigma).
Preparation of macrophage samples for Western blotting and RNase protection After transduction (MOI 600) and/or hypoxic exposure cells were lysed in SDS buffer and heated at 99°C for 5 min. Lysates were stored at −70°C until a protein gel and blot could be performed using standard conditions. Blots were probed with Rat anti-P4502B6 (Chemicon, CA, USA), anti-HIF-1␣ or HIF-2␣ (gift from P Maxwell, Oxford, UK). RNA was isolated using Trizol LS (Gibco). RNase protection was performed as described 18 using riboprobes complementary to HIF-1␣, HIF-2␣ and U6 small nuclear RNA.
Infiltration of primary human macrophages into tumour spheroids Spheroids were prepared by seeding 5 × 10 3 T47D cells in 100 l DMEM medium (supplemented with 10% FCS, 2 mm glutamine) into each well of a 2% molecular biology grade agarose (Sigma) coated 96-well tissue culture plate. Medium was aspirated and replaced every 3-4 days. After 10-14 days transduced macrophages were washed in PBS and 2 × 10 4 placed on each tumour spheroid. Excess macrophages were gently removed from the spheroid surface 48 h later and the medium replaced. The spheroids were fixed in histological formalin and either X-gal stained or wax embedded and sectioned by standard histological techniques. Sections were immunostained for CD68 and the lacZ gene product, ␤-galactosidase (rabbit polyclonal, 3prime → 5prime, CO, USA), using the CSA system of signal enhancement (Dako). Alternatively these spheroids were exposed to 0.1% oxygen for 16 h, fixed and stained with X-gal substrate. Spheroid photomicrographs were taken at ×4 or ×10 magnification.
For cytotoxicity experiments with CYP2B6 expressing macrophages, spheroids were infiltrated as above (MOIs were 1600 for Ad-CMV CYP2B6 and 2100 for Ad-OBHRE CYP2B6), washed, and treated with 0.5 mm cyclophosphamide for 7 days. Treated spheroids were fixed, processed as described and sections stained with haematoxylin and eosin to highlight cell morphology. For clonogenic survival determination, three spheroids from each group were disaggregated to form a cell suspension, diluted to 10 −1 to 10 −3 in DMEM, 10% FCS medium, and plated on six-well plates. Colonies of Ͼ50 cells were counted at the 10 −1 dilution.
